Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial).
Mohammad Shafi KuchayPushpender KhatanaMitali MishraParvathi SurendranParjeet KaurJasjeet Singh WasirHarmandeep Kaur GillApanshu SinghRujul JainChhavi KohliGazal BakshiVishnupriya RadhikaSumayya SaheerManish Kumar SinghSunil Kumar MishraPublished in: Acta diabetologica (2023)
Dapagliflozin complementary to basal-bolus insulin does not improve glycemia further over and above the basal-bolus insulin alone in hospitalized cardiac surgery patients. Dapagliflozin significantly increases plasma ketones levels. Safety of dapagliflozin in hospitalized patients needs further investigation. Trial registration ClinicalTrials.gov NCT05457933.
Keyphrases
- cardiac surgery
- study protocol
- type diabetes
- acute kidney injury
- end stage renal disease
- phase iii
- clinical trial
- ejection fraction
- chronic kidney disease
- phase ii
- newly diagnosed
- healthcare
- randomized controlled trial
- mental health
- prognostic factors
- peritoneal dialysis
- acute care
- palliative care
- emergency department
- open label
- oxidative stress
- metabolic syndrome
- weight loss
- double blind